Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green Sells 291 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 291 shares of Twist Bioscience stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $41.68, for a total value of $12,128.88. Following the sale, the senior vice president now directly owns 130,621 shares in the company, valued at $5,444,283.28. The trade was a 0.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Paula Green also recently made the following trade(s):

• On Thursday, March 6th, Paula Green sold 918 shares of Twist Bioscience stock. The stock was sold at an average price of $40.91, for a total value of $37,555.38.
• On Monday, February 3rd, Paula Green sold 1,259 shares of Twist Bioscience stock. The shares were sold at an average price of $49.35, for a total transaction of $62,131.65.
• On Friday, January 3rd, Paula Green sold 160 shares of Twist Bioscience stock. The stock was sold at an average price of $45.59, for a total transaction of $7,294.40.

Twist Bioscience Stock Performance

Twist Bioscience stock opened at $44.94 on Tuesday. The stock has a 50-day simple moving average of $45.42 and a 200 day simple moving average of $45.31. The stock has a market capitalization of $2.68 billion, a price-to-earnings ratio of -13.30 and a beta of 2.15. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 12-month low of $27.41 and a 12-month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. During the same period in the previous year, the firm posted ($0.75) earnings per share. The company’s revenue was up 24.1% on a year-over-year basis. On average, research analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on TWST. Wolfe Research started coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target for the company. TD Cowen reissued a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a report on Tuesday, November 26th. Scotiabank reaffirmed an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Robert W. Baird increased their price objective on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 4th. Finally, JPMorgan Chase & Co. lifted their price objective on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $54.40.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Arizona State Retirement System lifted its stake in shares of Twist Bioscience by 1.3% during the fourth quarter. Arizona State Retirement System now owns 16,985 shares of the company’s stock valued at $789,000 after acquiring an additional 219 shares during the period. Van ECK Associates Corp lifted its position in Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after purchasing an additional 267 shares during the period. Hillsdale Investment Management Inc. boosted its stake in shares of Twist Bioscience by 0.4% in the 4th quarter. Hillsdale Investment Management Inc. now owns 78,000 shares of the company’s stock valued at $3,625,000 after purchasing an additional 300 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Twist Bioscience by 2.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company’s stock worth $734,000 after buying an additional 363 shares during the period. Finally, Deerfield Management Company L.P. Series C raised its stake in shares of Twist Bioscience by 1.7% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 23,827 shares of the company’s stock worth $1,107,000 after buying an additional 403 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.